AdjuTec Pharma Completes Production of APC148 Drug Product for Phase 1

Oslo, Norway, 19 June 2024 – AdjuTec Pharma AS is a privately held company developing antibiotic resistance breakers. The Company successfully completed production of its lead product APC148 Thursday 13 June.

Adjutec recently received approval from the Swedish Medicinal Product Agency to start the first phase 1 study in healthy volunteers. The successful production of APC148 drug product at Rechon Life Science in Malmø completed the long journey of R&D efforts to reach clinical testing of the product. After all necessary quality control activities have been finalized and the product has been released, APC148 will be shipped to CTC, our clinical phase 1 CRO in Uppsala to prepare for a study start in September.

The Adjutec team recently pitched for a major grant/equity opportunity through the EIC program in Brussels. The grant and equity add to €14mill, will need matching with private capital and would finance the phase 1-2 program. End of phase-2 is an important clinical milestone that will de-risk the program significantly. Reaching the final pitch competition is a great achievement and a recognition of the importance of our project. A decision will be made in July.

About antimicrobial resistance (AMR) – https://www.who.int/news-room/fact-sheets/detail/antimicrobial-resistance

AMR is a global health threat with an estimated 5mill associated deaths, including 1.27mill deaths attributable to bacterial AMR in 2019. WHO has declared that AMR is one of the top 10 global public health threats facing humanity. Misuse of antimicrobials is the main driver in the development of drug-resistant pathogens. AMR results in prolonged hospital stays at intensive care units with increased costs to the healthcare system. Without effective antimicrobials, the success of modern medicine in treating and preventing infections during major surgery and cancer chemotherapy, can be jeopardized.

About AdjuTec Pharma

AdjuTec Pharma is a company that is dedicated to developing and providing novel antibiotic resistance breakers to the global market. The company technology offers a unique mechanism of action that inactivates bacterial defence enzymes and restores bacterial sensitivity to antibiotics. The company’s lead product is APC148, a selective zinc chelator targeting bacterial metallo-ß-lactamase (MBL) enzymes. The technology was invented by Professor Pål Rongved and his group at the Department of Pharmacy, University of Oslo. The Company is located at St. Olavs gate 5, 0165 - downtown Oslo.

For more information, please visit www.adjutecpharma.com

Please contact: info@adjutecpharma.com

Follow us on LinkedIn and Twitter